Breast Cancer Treatment and Management: A Clinical Overview

Clinical Note: For patients with high-risk features—such as large tumors ($\ge 2$ cm), grade 3 disease, or lymphovascular invasion (LVI)—clinicians should strongly consider a radiation boost to the tumor bed to minimize local relapse.

Systemic Therapy and Molecular Profiling

The transition from local to systemic management is governed by the tumor's molecular signature. The two most critical markers are Hormone Receptor (HR) status (estrogen and progesterone receptors) and HER2 expression.

HR+/HER2- Advanced Breast Cancer

In patients with hormone receptor-positive (HR+) and HER2-negative disease, endocrine therapy (ET) remains the backbone of treatment. This often involves aromatase inhibitors (e.g., letrozole, anastrozole) to reduce estrogen levels in postmenopausal women. To enhance the efficacy of ET, CDK4/6 inhibitors—such as palbociclib, ribociclib, and abemaciclib—are frequently used in combination to delay disease progression.

Targeted Therapies for Specific Mutations

As disease progresses, new mutations often emerge, necessitating a change in therapeutic strategy:

1. PIK3CA Mutations: Patients harboring these mutations may benefit from inhibitors like alpelisib or inavolisib.
2. ESR1 Mutations: The emergence of ESR1 mutations is a common mechanism of resistance to endocrine therapy. In these cases, drugs like elacestrant or camizestrant (a PROTAC Estrogen Receptor Degrader) have shown clinical utility.

HER2-Positive Disease

For patients with HER2 expression, treatment focuses on blocking the HER2 signaling pathway. This typically involves a combination of agents such as trastuzumab and pertuzumab. Recent advancements have also introduced antibody-drug conjugates (ADCs) like fam-trastuzumab deruxtecan-nxki for high-risk or recurrent cases.

Management of Metastatic Breast Cancer (MBC)

Metastatic breast cancer (Stage IV) requires a multidisciplinary approach focused on systemic control and symptom management.

Bone Metastases and Skeletal Health

Many patients with advanced disease experience lytic bone metastases, which increase the risk of fractures and pain. To mitigate these skeletal complications, clinicians prescribe bisphosphonates (such as zoledronic acid, pamidronate, or ibandronate) or denosumab.

The Challenge of Oligometastatic Disease

A subset of patients presents with oligometastatic disease, where cancer is present in a limited number of sites. While routine use of ablative treatments (like SBRT) for all oligometastatic patients has not yet proven to extend overall survival in all trials, an aggressive multimodality approach—combining locoregional therapy with "adjuvant-like" systemic therapy—may be considered for patients with favorable features, such as bone-only metastases or HER2+ status.

Exam Tip: When evaluating a patient for systemic therapy, always check for the presence of ESR1 or PIK3CA mutations, as these findings will fundamentally alter the choice of next-line endocrine or targeted agents.

Reconstruction and Survivorship

Beyond oncologic control, the management of breast cancer includes breast reconstruction, utilizing either implants or autologous tissue (e.g., TRAM or DIEP flaps). As patients transition into survivorship, care shifts toward long-term monitoring and managing the side effects of therapy, such as the contraindication of menopausal hormone therapy in survivors of hormonally mediated cancers.